Fate Therapeutics claims to make 15,000 cell therapy doses per cGMP run.
Fate Therapeutics shows potential to develop cell therapies from renewable cell lines at scale after experiencing early production success.
The change in focus from autologous to allogeneic cell therapies stands to remove the logistical challenges associated with approved CAR-Ts, Kymriah and Yescarta by ending the need to work with a patient’s own cells. However, relying on allogeneic products on donor cells comes with its risks.
However, they saw that Induced Pluripotent Stem Cells (iPSCs) can be engineered and expanded and used for its off-the-shelf cell therapies.
FT538, Fate’s fourth off-the-shelf, iPSC-derived natural killer cell therapy, recently came through a manufacturing run at their new San Diego site in support of an early-phase clinical trial in blood cancer patients.
Fate used the small-scale run to calculate the yield it could achieve from a cGMP campaign, projecting that it could make trillions of cells capable of filling 15,000 unit doses.
Immatics Cell Therapy Manufacturing Collaboration with UTHealth Extended.
Immatics recently announced the extension of its collaboration with UTHealth.
The newly extended collaboration will allow Immatics longer access to UTHealth’s state-of-art cGMP manufacturing infrastructure until the end of 2024. Enabling the continued production and supply of Immatics’ specialized, cell-based product candidates for testing in multiple clinical trials.
Steffen Walter, Chief Technology Officer at Immatics, said that they have forged a strong and productive partnership collaboration with UTHealth over the years, which resulted in the initiation of four ongoing clinical trials. They look forward to continuing this collaboration with UTHealth.
Fabio Triolo, Director at UTHealth, added that they also look forward to continuing their collaboration and further leveraging the potential of their manufacturing capabilities.
Researchers discovers new findings in using Gene Therapy for Reversal of Aging-Associated Pulmonary Fibrosis
A study conducted by CNIO researchers who have previously developed an effective therapy for mice with fibrosis caused by genetic defects in 2018, now found that the same therapy can successfully be used to treat mice with age-related fibrosis.
Idiopathic pulmonary fibrosis is a life-threatening disease for which there is currently no cure and that is associated with certain mutations or advanced age.
CNIO’s Maria Blasco, principal investigator of the study explains that the therapy was based on activating telomerase expression temporarily. A virus used as a telomerase gene carrier was injected intravenously into the mice. The effect was temporary, but lung tissue regeneration was successfully induced.
The study was funded by the Spanish Ministry of Science, Innovation and Universities, the Carlos III Health Institute, the Community of Madrid, the Botín Foundation and Banco Santander through Santander Universidades, and World Cancer Research.